Viloxazine
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 427 publications
Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making.
Journal: BMJ (Clinical research ed.)
Published: November 26, 2025
Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials.
Journal: Expert opinion on pharmacotherapy
Published: September 23, 2025
Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults.
Journal: CNS drugs
Published: June 02, 2025
Cognitive Impairment in Adult Attention Deficit Hyperactivity Disorder: Clinical Implications and Novel Treatment Strategies.
Journal: Clinics and practice
Published: May 24, 2025
Viloxazine Extended-Release Administered With Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Phase 4, Open-Label Trial.
Journal: Journal of child and adolescent psychopharmacology
Published: February 27, 2025
Real world pharmacovigilance comparison of viloxazine and dextroamphetamine adverse reaction profiles.
Journal: Scientific reports
Published: February 05, 2025
Clonidine oral suspension (Onyda XR) for ADHD.
Journal: The Medical letter on drugs and therapeutics
Published: January 06, 2025
Early Positive Report of Viloxazine for a Child with Hyperkinetic Autism.
Journal: Psychopharmacology bulletin
Published: January 02, 2025
Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Journal: The lancet. Psychiatry
Published: December 19, 2024
Last Updated: 02/24/2026